Transport and Metabolism of Tyrosine Kinase Inhibitors Associated with Chronic Myeloid Leukemia Therapy: A Review

Scientists focus on the pharmacokinetics of approved tyrosine kinase inhibitors related to chronic myeloid leukemia (CML) therapy to comprehend their specificity, tolerability, and off-target effects, which could help clinicians to make a patient-specific selection of CML drugs by considering concomitant diseases and risk factors to the patients.